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The objective was to evaluate the effect of an assessment strategy using the computer decision support system (the GRAIDS
software), on the management of familial cancer risk in British general practice in comparison with best current practice. The design
included cluster randomised controlled trial, and involved forty-five general practice teams in East Anglia, UK. Randomised to GRAIDS
(Genetic Risk Assessment on the Internet with Decision Support) support (intervention n¼23) or comparison (n¼22). Training in
the new assessment strategy and access to the GRAIDS software (GRAIDS arm) was conducted, compared with an educational
session and guidelines about managing familial breast and colorectal cancer risk (comparison) were mailed. Outcomes were
measured at practice, practitioner and patient levels. The primary outcome measure, at practice level, was the proportion of referrals
made to the Regional Genetics Clinic for familial breast or colorectal cancer that were consistent with referral guidelines. Other
measures included practitioner confidence in managing familial cancer (GRAIDS arm only) and, in patients: cancer worry, risk
perception and knowledge about familial cancer. There were more referrals to the Regional Genetics Clinic from GRAIDS than
comparison practices (mean 6.2 and 3.2 referrals per 10000 registered patients per year; mean difference 3.0 referrals; 95%
confidence interval (CI) 1.2–4.8; P¼0.001); referrals from GRAIDS practices were more likely to be consistent with referral
guidelines (odds ratio (OR)¼5.2; 95% CI 1.7–15.8, P¼0.006). Patients referred from GRAIDS practices had lower cancer worry
scores at the point of referral (mean difference  1.44 95% CI  2.64 to  0.23, P¼0.02). There were no differences in patient
knowledge about familial cancer. The intervention increased GPs’ confidence in managing familial cancer. Compared with education
and mailed guidelines, assessment including computer decision support increased the number and quality of referrals to the Regional
Genetics Clinic for familial cancer risk, improved practitioner confidence and had no adverse psychological effects in patients. Trials
are registered under N0181144343 in the UK National Research Register.
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Clinical translation of advances in understanding the genetics of
common disease will require primary care practitioners to play an
increasing role in providing genetic advice (Qureshi et al, 2004).
Cancer genetics provides a model for the genetics of common
disease and their clinical implications for primary care (Emery
et al, 2001). The discovery of genes that place individuals at
increased risk of breast, ovarian and colorectal cancer has had
important and immediate clinical applications (Wooster and
Weber, 2003). Key tasks for primary care practitioners include
identifying individuals likely to be at increased genetic risk and
advising those for whom genetic testing and increased disease
surveillance offer little benefit. Previous audits of referrals to
familial cancer clinics in the UK show that approximately
30% of referrals from general practice are for patients whose
risk is not significantly raised on current evidence (Wonderling
et al, 2001).
Previously we reported experimental and qualitative evaluations
of a prototype computer decision support tool for the management
of familial cancer risk in primary care (Emery et al, 1999, 2000).
These demonstrated the functionality and design of the software,
and also demonstrated its potential to improve general practi-
tioners’ management decisions in simulated cases. This work
underpinned the development of the GRAIDS software (Genetic
Risk Assessment on the Internet with Decision Support) (Emery,
2005). We now report the results of a randomised controlled trial
of an assessment strategy using the GRAIDS software in British
general practice compared with best current practice.
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sMATERIALS AND METHODS
Design
This was a pragmatic cluster randomised controlled trial with
randomisation, at the level of the general practice, to GRAIDS or
current ‘best practice’ (Campbell et al, 2000). Outcomes were
measured at practice, practitioner and patient levels. Within the
intervention group, we used an exploratory design with fixed and
adaptive arms based on a threshold of software use.
Objectives
We hypothesised that the new assessment strategy (GRAIDS)
would result in a greater proportion of referrals to the Regional
Genetics Clinic that were consistent with the risk assessment
guidelines for familial breast/ovarian cancer and familial colorectal
cancer, than current best practice. Secondary hypotheses included
that patients from intervention practices would have greater
knowledge about familial cancer without higher cancer worry, at
the point of referral than from comparison practices. Within the
GRAIDS practices, we predicted that patients who were not
referred would have lower risk perception and lower cancer worry
than those who had been referred, and that the intervention would
increase practitioner confidence in management.
Participant practice teams We invited 170 general practice teams
in the Eastern Region of England, with a minimum of three full-
time-equivalent doctors, to join the trial. Inclusion criteria were
that the practice was connected to the health service intranet
(NHSnet) and referred patients with a family history of cancer to
the Eastern Regional Genetics Clinic at Addenbrookes Hospital
NHS Trust, Cambridge. Forty-five practice teams agreed to
participate and were randomised to GRAIDS (intervention) or
best practice (comparison) strategies.
Interventions and recruitment of patients Intervention; GRAIDS
strategy: All general practitioners and practice nurses attended a
45-min educational session on cancer genetics, delivered at their
general practice. They were also introduced to the principles of
the GRAIDS intervention. Each practice team selected a single
clinician (general practitioner or practice nurse) to act as the ‘lead
clinician’ to manage all patients who expressed concerns about
their family history of breast or colorectal cancer. In larger
practices, this role could be shared by two clinicians. The lead
clinicians attended a further 90-min interactive training session to
learn to use the GRAIDS software.
The GRAIDS software links a user-friendly pedigree-drawing
tool to patient-specific management advice regarding a family
history of breast/ovarian and colorectal cancer, and provides
additional numerical risk information about breast cancer
(Supplementary Figure 1). The software applies Cyrillic technology
(Benson, 2000) to create pedigrees and assesses familial cancer risk
using two parallel methods: the implementation of risk assessment
guidelines and an epidemiological risk model. In the GRAIDS
Trial, we implemented the regional guidelines for familial breast/
ovarian cancer and familial colorectal cancer (Table 1). In
addition, the Claus model (Claus et al, 1991) was applied to
provide breast cancer risk information in a range of verbal and
graphical modes. The regional guidelines are principally designed
to assess cancer risk and categorise people into increased risk or
population risk; the familial breast/ovarian cancer guidelines
additionally categorise women into moderate and high risk, the
latter representing people who are also at clinically significant risk
of carrying a BRCA1/2 mutation. The guidelines are used to inform
referrals for those at increased risk of cancer to the Regional
Genetics Clinic.
The GRAIDS software operates on a central server within a
computer network. In this trial, the software was installed on a
secure server at the Addenbrookes Hospital NHS Trust. Each lead
clinician accessed the GRAIDS software via their NHSnet
connection, using a practice-specific password.
Patients were invited to participate if they expressed concerns
about their family history of breast or colorectal cancer in a
consultation. They were referred to the lead clinician and given a
detailed explanation of project participation, and a family history
questionnaire to complete before the next consultation. The family
history questionnaire was designed as part of the GRAIDS strategy
to improve the accuracy of the family history information
provided by participants.
Fixed and adaptive sub-groups: Within the intervention arm,
practices were randomised to either a fixed or adaptive sub-group.
In the adaptive group, the lead clinician was interviewed 3 months
after training, if frequency of software usage was below a
predefined level based on size of the practice population. The
interview identified reasons for low usage and aimed to resolve any
problems using the software. In the fixed group, practices received
the intervention as described above, with no opportunity for
additional input. The purpose of this was to include the option of
additional clinician training or adjustment to the software in the
adaptive arm during the trial, to increase software use.
Comparison; current ‘best practice’: All general practitioners and
practice nurses attended a 45-min educational session on cancer
genetics delivered at their general practice (Watson et al, 2001).
Afterwards, they were each mailed a paper copy of the regional
guidelines for familial breast/ovarian cancer and familial colorectal
Table 1 Eastern Region Familial Breast/Ovarian and Colorectal Cancer
Guidelines
Breast/ovarian cancer
High risk criteria:
1. Two relatives who are FDR of each other with breast
cancer where average age of diagnosis is under 40 years.
2. Three or more relatives who are FDR of each other with
ovarian or breast cancer, where average age of diagnosis
is under 60 years
3. Four or more relatives who are FDR of each other with
breast or ovarian cancer at any age
4. One individual in family with breast and ovarian cancer
Moderate risk:
1. One female FDR with breast cancer o40 years
2. One paternal female SDR with breast cancer o40 years
3. One female FDR with bilateral breast cancer o60 years
4. Two FDR/SDR with breast cancer o60 years or ovarian
cancer any age
5. Three FDR/SDR with breast or ovarian cancer any age
6. One male FDR with breast cancer any age
Colorectal cancer
1. One affected FDR o45 years
2. One affected FDR and 1 affected SDR on same side of
family
3. Two FDR (inc both parents)
4. Three affected relatives any age
‘Affected’ means diagnosed with either of the following:
a. CRC, colorectal cancer: 3X adenomatous polyps, one
adenomatous polyp o60 years.
b. HRC, HNPCC-related cancer: endometrium, ovary,
gastric, small bowel, ureter, renal pelvis
There should be at least one CRC in the family.
Abbreviations: CRC, colorectal cancer; FDR, first-degree relative; HRC, HNPCC-
related cancer; SDR¼second-degree relative.
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participate in the trial, until they were referred to the Regional
Genetics Clinic.
Measures
Randomised comparisons Practice level, principal outcome and
appropriate referral rates: We audited all referrals to the Regional
Genetics Clinic from trial practices during the study period.
‘Appropriateness’ of referral was defined in two ways: (1)
(principal outcome) consistency of the family history reported in
the general practitioner’s referral letter with the regional guidelines
for familial breast/ovarian and colorectal cancer; (2) (secondary
outcome) the final expert risk assessment conducted by the
Regional Genetics Clinic staff among attending patients, according
to current best evidence, to determine if the patient was at
significantly increased risk of familial cancer. A ‘relevant referral’
was for the individual person referred, rather than their relative,
and about their family history of either breast, ovarian or
colorectal cancer.
Patient level: (referred patients only): Questionnaires were sent
to patients when a referral was received at the Regional Genetics
Clinic. The questionnaire measured risk perception, knowledge
about familial cancer and cancer worry using disease-specific
measures. Items were taken from established instruments identi-
fied in a systematic review of genetic counselling for familial
cancer (Braithwaite et al, 2004). Risk perception was measured on
a scale of 1–7, relative to the general population, considering 1 as
‘much less likelyy’ and 7 as ‘much more likely to develop breast/
bowel cancer than other people of your age’. For one analysis,
responses of 1–4 were classified as ‘population risk’ and 5–7 as
‘increased risk’. This was compared to the risk assessment
conducted by the Regional Genetics Clinic to classify patients
as under-estimators, accurate-estimators and over-estimators
(Watson et al, 1999).
Comparisons within GRAIDS arm only Practitioner level:W e
measured the frequency of use of the software remotely from
server activity. A questionnaire examined the attitudes of lead
clinicians towards using the GRAIDS software, their confidence in
risk assessment and managing patients with a family history of
cancer, problems using the software and intention to continue
using it (Braithwaite et al, 2002). This questionnaire was provided
before the lead clinician training and 2 weeks and 12 months after.
Lower scores on these instruments reflected more positive
attitudes or greater agreement with a statement. Data on the
length of consultation with the lead clinician were obtained from
electronic appointment systems in 20 intervention practices.
Patient level: Those in the GRAIDS arm who were not referred,
were sent questionnaires 2 weeks after their consultation with the
lead clinician for comparison with those referred from GRAIDS
practices.
Sample size
Twenty intervention and 20 comparison practices allowed an
estimation of effect size on appropriateness of referrals for familial
cancer with a precision of 711% as measured by the 95%
confidence interval (CI) width, equivalent to 80% power to detect a
15% difference between arms. Ten practices per intervention arm
also provided 80% power to detect a 25% relative difference
(adaptive vs fixed arms) in use of software at 1 year, and 33%
relative difference at 3 months using practice-level t-tests at the 5%
level of significance. Sample sizes were determined through
simulation using S-plus 2000 software (MathSoft Inc., Seattle,
WA, USA).
Randomisation
Practices were randomised using a partial minimisation procedure
that dynamically adjusted the randomisation probabilities in order
to provide a balance between arms in the mean number of patients
aged 20–50 years per practice and to achieve the planned
allocation ratio of 1:1:2 for adaptive intervention, fixed
intervention and comparison arms. Randomisation was conducted
independently by a statistician (ATP) who had no contact with
practices.
Statistical methods
Rates of software use were calculated, for each practice, as the
annual number of software uses per 10000 registered patients, and
were compared between fixed and adaptive arms using a t-test. The
same method was used to compare referral rates between GRAIDS
and comparison arms. The binary outcomes of referral appro-
priateness were analysed using a generalised linear mixed-effects
model, allowing for practice as a random effect in order to account
for the cluster randomised design.
Patient questionnaire outcomes were analysed using linear or
generalised linear mixed-effects models as appropriate, allowing
for practice as a random effect. Numerical knowledge and worry
scales were analysed as continuous variables.
Within the GRAIDS arm, practitioner outcomes were analysed
using a paired t-test to compare attitudes towards using the
GRAIDS software 2 weeks and 12 months after training with pre-
training levels. A significance level of 5% was used for all tests. All
analyses were conducted on an intention-to-treat basis. Analysis
was carried out using SPSS version 12.5 and R version 2.0.1.
Ethical and research governance approval for the study
were received by the Eastern Multi-Centre Research Ethics
Committee and the relevant primary care trusts, respectively. For
the intervention arm, participants signed a consent form at
the beginning of their consultation with the lead clinician. For the
comparison arm, consent was assumed from return of the
questionnaire.
RESULTS
Practice characteristics
All 45 practice teams were in the trial for a minimum of 12 months
and none withdrew. Twenty-three practice teams were randomised
to the intervention and 22 to the comparison group. Table 2
presents the main characteristics of practices and participants
in the two trial arms. There were no statistically significant
Table 2 Characteristics of practices and participants in trial arms
Intervention
practices
Comparison
practices
Practice factors at baseline
Number 23 22
Mean list size (s.d.) 8787 (3840) 8718 (4614)
Mean number of patients aged 20–50
years (s.d.)
3881 (1747) 3843 (2136)
Participant factors at baseline
No. in trial not referred to RGC 78 Unknown by design
No. relevant referrals detected at RGC 162 84
No. (%) referred to RGC for family history of
Breast/ovarian cancer 86 (53) 60 (71)
Colorectal cancer 55 (35) 23 (27)
Both 21 (13) 1 (1)
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sdifferences in practice characteristics at baseline. The flow of
participants through the trial is shown in Figure 1.
One hundred and sixty-two relevant referrals were registered at
the Regional Genetics Clinic from GRAIDS practices (162/168
referred) and 84 from comparison practices during the trial. These
denominators were used for analyses of referral rates. One
hundred and sixty-nine participants had attended their Regional
Genetics Clinic appointment by the end of the trial and
contributed to the comparison of appropriateness of referral
against final Regional Genetics Clinic risk assessment (GRAIDS
arm: 117/162 participants, Comparison arm: 52/84 participants).
Twenty-two participants were referred for a family history of both
breast and colorectal cancer, and therefore contributed two risk
assessments in the analyses of appropriateness of referral letters
(GRAIDS arm 21; comparison arm 1). Sixteen of these attended the
Regional Genetics Clinic within the trial period (GRAIDS arm 15;
comparison arm 1). In total, 132 risk assessments in the GRAIDS
arm and 53 in the comparison arm were obtained. Questionnaires
were returned by 75% of referred participants from the GRAIDS
arm and 64% from the comparison arm.
Randomised comparisons
Practice level
Principal outcome: appropriate referral rates: There were 162
relevant referrals made by the GRAIDS practices and 84 referrals
by the comparison practices to the Regional Genetics Clinic for
familial cancer risk assessment. GRAIDS practice teams referred a
mean 6.2 (standard deviation (s.d.), 3.1) per 10000 registered
patients per practice per year compared to 3.2 (s.d., 2.8) per 10000
registered patients per practice per year in comparison practices
(mean difference 3.0; 95% CI 1.2–4.8, P¼0.002).
A significantly higher proportion of referral letters was
consistent with the regional guidelines in the intervention arm
than in the comparison arm (breast cancer alone and breast and
colorectal cancer combined; Table 3). There was no overall
difference between groups in the final risk assessment conducted
by staff at the Regional Genetics Clinic. This was due to the large
proportion of referrals from GRAIDS practices for family history
of colorectal cancer that, while consistent with regional guidelines,
on final risk assessment by the Regional Genetics Clinic staff, were
deemed to be at population risk. Participants referred from
intervention practices about colorectal cancer risk were signifi-
cantly more likely to be at population risk than those from
comparison practices when their risk was determined at the
Regional Genetics Clinic, even though the referral letter was
consistent with increased risk defined by the familial colorectal
cancer guideline. The referrals about colorectal cancer did not
account for the significantly higher number of referrals overall
from intervention practices.
Patient level
There were no significant differences in knowledge scores between
patients referred from intervention or comparison practices.
Cancer worry scores were significantly lower in patients from
intervention practices than those from comparison practices.
There was no difference in mean risk perception between patients
referred from intervention or comparison practices (Table 4).
There was a non-significant trend towards more accurate risk
perception at the point of referral in intervention patients with
fewer overestimating risk (odds ratio (OR) 1.50, 95% CI 0.62–3.67;
P¼0.36) (Table 5).
Comparisons within GRAIDS arm only
Practitioner level
Software use: The software was used with patients 219 times
during the trial; this equates to a mean use of 8.27 per 10000
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Figure 1 Changes in lead clinicians’ attitudes towards the GRAIDS software, and confidence in managing familial cancer over time (mean score with 95%
CI shown; P-values refer to comparison of pre- and post-training responses).
Table 3 Proportion of referrals meeting guidelines and number of
referrals for increased risk, as determined by RGC, by randomised group
Intervention Control Odds ratio (95% CI)
Proportions meeting referral guidelines
Breast 93% (99/107) 73% (44/60) 4.5 (1.6–13.1)
Bowel 99% (75/76) 92% (23/25) 6.5 (0.5–83.7)
Combined 95% (174/183) 79% (67/85) 5.2 (1.7–15.8)
P¼0.006
Proportions with increased RGC risk level
Breast 77% (60/78) 70% (23/33) 1.4 (0.6–3.5)
Bowel 56% (30/54) 85% (17/20) 0.2 (0.1–0.8)
Combined 68% (90/132) 75% (40/53) 0.7 (0.3–1.5)
P¼0.35
Abbreviations: CI, confidence interval. Odds ratios and 95% confidence intervals
shown for intervention vs comparison, allowing for the cluster randomised design.
NB: 21 participants were referred for a family history of breast and colorectal cancer,
of whom 15 attended the RGC; these participants contribute two risk comparisons in
the analyses.
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in frequency of use of the software during the first 12 months of
the trial.
Fixed and adaptive arms: All lead clinicians from the 11 practices
in the adaptive sub-group were interviewed at 3 months due to
lower than predicted software use. No specific problems in using
the software were identified. All lead clinicians felt low use
reflected low patient demand. There was no difference in software
use between fixed and adaptive practices at 12 months: fixed arm,
mean 7.8 (s.d., 4.7) uses per practice per year per 10000 registered
patients; adaptive arm, mean 8.8 (s.d., 4.1); mean difference 0.9;
95% CI  2.8–4.8; P¼0.60). We therefore combined data from the
fixed and adaptive sub-groups of the intervention for all
subsequent analyses.
Practitioner confidence and attitudes: Lead clinicians’ confidence
in managing people with a family history of cancer increased
significantly after training and this increase was maintained at 12
months (Figure 2). Their attitudes towards the software were
generally positive, such that it was felt to be simple, easy, beneficial
and cost-effective and these positive attitudes remained at 12
months (Figure 2). However, there was some reduction over time,
in agreement with the statement that the software enhanced
consultations (mean score 2.1 (s.d., 0.8) post-training; 3.0 (s.d.,
1.7) at 12 months; mean change 0.8 95% CI 0.1–1.6; P¼0.04;
n¼26) and persistent agreement that it would prolong consulta-
tions (mean score 2.5 (s.d., 1.2) post training; mean score 2.3 (s.d.,
1.2) at 12 months). All but one lead clinician intended to continue
using the software if it remained available. Median consultation
time with the lead clinician was 28min.
Patient level
A total of 219 patients received the GRAIDS intervention, of whom,
141 were referred to the Regional Genetics Clinic. A further 27
patients were referred to the Regional Genetics Clinic from
GRAIDS practices without a GRAIDS consultation. Of the 168
referrals, 162 were identified at the Regional Genetics Clinic and
were for relevant cancers. The 78/219 patients not referred were
identified by the consent procedures. Risk perception was
significantly lower in patients not referred to the Regional Genetics
Clinic than in those referred.
DISCUSSION
Practice team access to a family history assessment strategy using
the GRAIDS software resulted in increased referral rates from
primary care to a regional genetics clinic for familial breast and
colorectal cancer, compared with current best practice. Referrals
from GRAIDS practices were more appropriate than from
comparison practices, when judged by their consistency with
referral guidelines, the most relevant measure of general practi-
tioners’ clinical behaviour. Cancer worries were lower among
patients referred from GRAIDS practices than from comparison
practices. For the GRAIDS arm, patients who were not referred had
lower cancer risk perception than those who were. Clinicians were
generally positive about the software and intended to continue to
use it if available.
Limitations of design
Cluster randomisation at practice level to intervention and
comparison strategies is the design of choice when the intervention
is applied at that level (Donner, 2000). It avoids contamination
between arms, which can reduce differences observed, but can
pose problems in equivalence of recruitment and consent across
arms. Thus we recruited patients in the GRAIDS arm as they
consulted their GP. However, we wished in the comparison arm to
mimic as closely as possible routine best practice (Watson et al,
2002). We therefore did not recruit patients who expressed
concerns about their family history of cancer in this arm, to avoid
an intervention effect by, for example, raising patient expectation
and increasing clinician referrals independent of usual best
practice. Consent to data collection in the comparison arm was
seen only among those referred to the regional clinic. This meant
that we were unable to collect data on patients in comparison
practices, who presented but were not referred to the Regional
Genetics Clinic.
The design precluded direct comparison of practice-based
recruitment rates in the two arms; we therefore analysed referrals
standardised by practice-registered population, where appropriate.
Differences in principal referral outcomes between arms are thus
an unbiased estimate of differences between the two overall service
models, except for the timing of consent, the effect of which we
believe would be small and not create any systematic bias.
Table 4 Patient knowledge, cancer worry and risk perception mean scores (standard deviations), and mean differences allowing for cluster randomised
design
Intervention arm
Not
referred Referred
Mean
difference Comparison arm
Mean difference
between referred
populations
(95% CI)
Knowledge breast cancer NA 5.77 (2.90) NA 5.66 (2.78) 0.11 ( 1.05–1.27)
n¼65 n¼38
Knowledge colorectal cancer NA 5.50 (2.46) NA 4.86 (3.30) 0.64 ( 1.01–2.29)
n¼44 n¼14
Cancer worry 4.95 (2.99) 5.74 (3.04) 0.79 ( 0.19–1.76) 7.18 (3.43)  1.44 ( 2.64 to  0.23)*
n¼57 n¼110 n¼51
Risk perception 4.25 (0.80) 4.99 (1.14) 0.74 (0.38–1.09)** 5.04 (0.88)  0.09 (0.34 to  0.51)
n¼51 n¼104 n¼47
Abbreviations: CI, confidence interval; NA, not analysed since no hypothesised difference. *P¼0.02; **Po0.0001.
Table 5 Accuracy of patients’ risk perception compared with Regional
Genetics Clinic assessment
Under-estimator Accurate assessor Over-estimator
Comparison 9 (23%) 22 (55%) 9 (23%)
Intervention 18 (21%) 59 (68%) 10 (11%)
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sKey findings
This is the first report of a clinical trial demonstrating the value of
family history assessment software designed for general practice.
The trial design accounted for many of the recognised flaws in past
trials of computer decision support systems (Mitchell and Sullivan,
2001). A previous study of mailing a CD Rom containing electronic
guidelines for familial breast cancer to general practitioners in
Scotland found minimal uptake of the software (Wilson et al,
2005). Our intervention differed in several critical ways: the
software had greater utility by supporting collection of family
history information and creating a pedigree; it made patient-
specific recommendations about management at the point of
decision; clinicians received interactive training in its use and the
service model of training a single clinician in a practice led to
more frequent use than if all practitioners had been trained
(Kawamoto et al, 2005). The trial was testing the service model
of providing a risk assessment service in the practice by
supporting a single clinician in the practice regardless of
background knowledge or interest. In some practices the lead
clinician may have had a specific interest in familial disease or
computer support, although to our knowledge this was only true in
one practice. Over a quarter of practice teams approached were able
to participate, a recruitment rate consistent with similar primary care
trials (Montgomery et al, 2000). Practices recruited into the trial are
likely to reflect the teams of the future who will be leading the
incorporation of genetic medicine into practice (Rogers, 1995).
The GRAIDS intervention resulted in significantly more referrals
that were consistent with referral guidelines, for breast cancer
alone and combined with colorectal cancer. This difference was not
apparent when appropriateness of referral was judged on the final
Regional Genetics Clinic risk assessment; indeed the reverse was
seen for colorectal cancer. This may reflect differences in the
validity of self-reported family history of cancer across disease
sites, which is usually confirmed by the genetics clinic (Ziogas and
Anton-Culver, 2003). More importantly it reflects differences in
the complexity and accuracy of the guidelines. The familial
breast cancer guidelines are more complex than for colorectal
cancer with several more criteria that define moderate and high-
risk groups. Consequently they are more specific, but more
difficult to implement in general practice. Computer implementa-
tion of familial breast cancer guidelines is more likely therefore to
have a positive effect. The familial colorectal cancer guideline
attempted to account for additional cancers associated with
hereditary non-polyposis colon cancer (HNPCC), while still
capturing individuals at moderate risk, and were therefore less
specific. As a result, when applied rigidly by the software,
practitioners made more referrals that were subsequently assessed
as at population risk by the Regional Genetics Clinic, even though
the referral would be considered ‘appropriate’, as it met the
category for increased risk in the familial colorectal cancer
guideline. This highlights the need for accurate guidelines for familial
colorectal cancer to underpin decision support in primary care,
similar to those published for breast cancer (McIntosh et al, 2004).
Current criteria to identify individuals with potential HNPCC, such as
the modified Bethesda criteria, aim to identify only high-risk
individuals, and would fail to identify those at moderately increased
risk, who may also benefit from referral (Umar et al, 2004).
Randomised (45 practices)
Allocated to comparison arm (22 practices) Allocated to intervention arm (23 practices)
219 participants received intervention
27 participants did not receive intervention, but 
were referred to RGC for concerns about family 
history relevant cancer
84 participants referred to RGC for 
concerns about family history 
relevant cancer 78 participants not referred to RGC
Questionnaire
84 sent; 54 responded (64%)
168 participants referred to RGC
Questionnaire
153 sent; 114 responded (75%)
Delayed referral option (n=2) 
No address on consent form  (n=3) 
No family history of relevant cancers (n=7)
Referral  not detected in time to send questionnaire (n=8)
Referral never detected at RGC (n=4)
Referred for other relatives (n=1)
No family history of relevant cancers (n=2)
Assessed for eligibility (170 practices)
Excluded: 
Declined to participate (125 
practices)
Participants not referred to RGC.
Number unknown by design
52 participants attended RGC
53 risk assessments obtained*
117 participants attended RGC
132 risk assessments obtained*
* 22 participants were referred for both breast and colorectal cancers; 16 attended RGC and thus contribute 
two RGC risk assessments
Questionnaire 
66 sent; 57 responded  (86%)
CONSORT flowchart
Figure 2 CONSORT Flowchart.
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breast and colorectal cancer, and reassuring the majority who are
unlikely to benefit from referral is an important outcome of this
trial. Although it resulted in increased referrals, which in the
United Kingdom might threaten overstretched regional genetics
services, it is the role of primary care to identify patients who
might benefit most from specific referral, in this case for genetic
counseling (Hayflick et al, 1998). There is growing evidence of
benefit for a range of surveillance and prophylactic measures for
individuals at increased risk of breast and colorectal cancer
(Cuzick et al, 2003; Dove-Edwin et al, 2005; Leach et al, 2005).
Access to predictive genetic testing can inform patients’ decisions
about prophylactic surgery and other preventive strategies
(Meijers-Heijboer et al, 2000).
Patients referred from intervention practices reported signifi-
cantly lower cancer worry than those from control practices. This
was not mediated by risk perception or the knowledge items
we measured. It is possible that the longer and more detailed
assessment in primary care better prepared patients for referral
with consequent reduction in anxiety. Alternatively, the GRAIDS
intervention may have resulted in a different population referred
to the Regional Genetics Clinic, who would not usually have been
referred. Participants who were not referred from intervention
practices showed lower cancer worry and mean risk perception
than those who were referred. While acknowledging the absence of
baseline data, this suggests that the intervention helps clinicians to
reassure patients at population risk of familial cancer and manage
them in primary care.
The intervention increased GPs’ confidence in managing familial
cancer, an area of medicine that is relatively new and complex
from a primary care perspective (Emery et al, 2001). Clinicians
were generally positive about the software in terms of simplicity
and utility. However, concerns were evident about the time taken
to conduct a consultation using the software. At the time of the
trial, the majority of practices had limited bandwidth available via
their NHSnet connection, making the software relatively slow to
run. Recent expansion of broadband connections to practices in
the UK would reduce the consultation time. However, this type of
consultation cannot be conducted in a ‘standard 10min’, as is true
for a growing number of complex conditions managed in primary
care (Freeman et al, 2002). What may be required is a brief,
sensitive triage tool that identifies people with a family history of
cancer and other common familial conditions for a more detailed
assessment using GRAIDS-based software.
There is growing interest in the broader application of the family
history of common disease in preventive health (Yoon et al, 2003).
The Center for Disease Control has recently developed a similar
electronic family history tool for use in primary care that is
undergoing evaluation (Yoon and Scheuner, 2003). This trial
demonstrates the potential of the GRAIDS software to improve the
management of familial cancer in primary care, assuming the
accuracy of current risk assessment guidelines. The software is
now being developed to implement validated risk-assessment
guidelines for other common familial conditions, to support the
broader management of the family history of common disease in
primary care.
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